Bindoclav Suspension 125-31.25 mg /5 ml / 250 mg 62.5 mg /5 ml POWDER FOR SUSPENSION
PDF Leaflet Revision Date: 29 January 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of infections caused by amoxicillin-resistant organisms.
Dosage (summary)
Children 2-12 years: 25-50 mg/kg/day in divided doses every 8 hours.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use in pregnancy not established; avoid breastfeeding due to potential infant sensitization.
Key Drug Interactions
- May reduce efficacy of oral contraceptives
- Increased rash with allopurinol
- Tetracyclines may interfere with effects
Contraindications
- Hypersensitivity to penicillins or cephalosporins
- History of jaundice/hepatic dysfunction with amoxicillin/clavulanic acid
Common side effects
- Nausea
- Diarrhoea
- Skin rash
- Dizziness
Counselling Points
- Take at the start of a meal
- Monitor for allergic reactions
- Avoid alcohol during treatment
Serious warnings
- Serious hypersensitivity reactions
- Pseudomembranous enterocolitis
- Prolonged use may lead to superinfections
Important Disclaimer
The Bindoclav Suspension 125-31.25 mg /5 ml / 250 mg 62.5 mg /5 ml POWDER FOR SUSPENSION professional information leaflet below is the property of Aurogen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
